# PROSPERO Registration Form

**Impact of Air Pollution on Vaccine Effectiveness: Systematic Review and Meta-Analysis**
**Registration Number:** CRD42024567892
**Date of Registration:** December 12, 2025
**Date of Last Updated:** December 18, 2025
**Registration Status:** Completed

---

## Section 1: Review Title
**Review Title:** Impact of Ambient Air Pollution (PM2.5, NO‚ÇÇ, O‚ÇÉ) on Vaccine Effectiveness in Real-World Populations: A Systematic Review and Meta-Analysis

**Alternative Title:** Air Pollution Diminishes Human Vaccine Responses: Evidence from Systematic Review of Real-World Effectiveness Studies

**Keywords:** Air pollution, PM2.5, nitrogen dioxide, ozone, vaccine effectiveness, vaccines, immunological response, meta-analysis, systematic review

---

## Section 2: Review Team

**Review Lead:**
- **Title and Name:** Dr. Research Automation System
- **Affiliation:** Environmental Epidemiology Research Institute
- **Email:** air.pollution.vaccine@example.edu
- **Phone:** +1-555-0101

**Review Team Members:**
1. **Lead Researcher:** Epidemiology specialist in environmental exposure assessment
2. **Statistical Lead:** Meta-analysis methodology and biostatistics expert
3. **Content Expert:** Immunologist with vaccine response specialization
4. **Information Specialist:** Systematic review database and search strategy expert

**Review Support Team:**
- **Peer Review:** External experts in air pollution toxicology and vaccine immunology
- **Technical Support:** Biostatistician for methodological validation

---

## Section 3: Review Questions and Objective(s)

### Research Questions

**Primary Question:**
Does chronic exposure to ambient air pollution (PM‚ÇÇ.‚ÇÖ particulate matter, NO‚ÇÇ nitrogen dioxide, and O‚ÇÉ ozone) reduce the effectiveness of routinely administered vaccines (e.g., influenza, COVID-19, pneumococcal, hepatitis B) in human populations, as measured by real-world clinical effectiveness against vaccine-preventable diseases?

**Secondary Questions:**
1. What are the quantitative effects of different air pollutants (PM‚ÇÇ.‚ÇÖ, NO‚ÇÇ, O‚ÇÉ) and pollution concentration bands on vaccine effectiveness across various vaccine types?
2. What are the dose-dependent relationships between air pollution exposure levels and vaccine effectiveness, including identification of threshold effects?
3. Which population subgroups show greatest vulnerability to air pollution-vaccine interactions (e.g., children, elderly, pregnant women)?
4. Are there specific vaccine types (live-attenuated, inactivated, mRNA, viral vector) that show differential susceptibility to air pollution exposure effects?

### Review Objectives

**Primary Objective:**
To synthesize evidence from epidemiological studies examining the impact of ambient air pollution on vaccine effectiveness in real-world settings, providing quantitative effect estimates for policy and clinical decision-making.

**Secondary Objectives:**
1. **Quantify Dose-Response Relationships:** Establish linear/logarithmic relationships between pollution exposure and vaccine effectiveness reduction
2. **Identify Vulnerable Populations:** Determine age groups, geographical regions, and socioeconomic subgroups at greatest risk
3. **Support Environmental Policy:** Provide evidence for air quality standards as indirect vaccine promotion strategy
4. **Guide Vaccination Strategy:** Inform timing of vaccinations and potential need for additional booster doses in polluted regions

### Rationale
Air pollution affects nearly 80% of the global population, with emerging evidence suggesting immune dysregulation affecting vaccine responses. The COVID-19 pandemic highlighted urgent need for understanding environmental factors influencing vaccine effectiveness. No comprehensive systematic review exists synthesizing air pollution-vaccine interactions across real-world effectiveness studies.

**Public Health Impact:** Results will inform vaccination programs in polluted regions and support air quality regulatory decisions affecting millions of global vaccine recipients.

**Research Gap Addressed:** While laboratory studies suggest air pollution-immune interactions, systematic review of real-world vaccine effectiveness studies remains critically needed.

---

## Section 4: Study Eligibility Criteria

### Types of Study to be Included
**Study Design:** Prospective cohort studies, retrospective cohort studies, nested case-control studies, ecological studies with strong methodological rigor, and population-based vaccine effectiveness studies.

**Condition or Domain:** Chronic ambient air pollution exposure measured at individual or community level, with vaccine effectiveness as primary outcome.

**Intervention(s):**
- **Pollutants:** PM‚ÇÇ.‚ÇÖ (particulate matter ‚â§2.5 microns), NO‚ÇÇ, O‚ÇÉ, traffic-related pollution, and multi-pollutant mixtures
- **Exposure Assessment:** Quantitative measurements from monitoring stations, satellite-derived estimates, land-use regression models, or validated exposure prediction models
- **Exposure Duration:** Minimum 24-hour acute exposure; preferably chronic long-term exposure (weeks to years)

**Comparator(s):**
- **Control Groups:** Same population vaccinated against same pathogens but with lower air pollution exposure
- **Within-Study Control:** Population-level comparisons during high vs. low pollution periods
- **Between-Study Control:** Vaccinated populations in clean air vs. polluted environments

**Outcome(s):**
**Primary Outcomes:**
- **Vaccine Effectiveness:** Relative risk (RR) or hazard ratio (HR) of vaccine-preventable disease in vaccinated vs. unvaccinated groups, across pollution exposure gradients
- **Effectiveness Range:** Point estimates and 95% confidence intervals comparing polluted vs. clean air environments
- **Clinical Verification:** Laboratory-confirmed disease outcomes requiring hospitalization, severe illness, or mortality

**Secondary Outcomes:**
- **Seroconversion Rates**: Antibody response magnitudes across pollution exposure levels
- **Immune Intercept Modification**: Altered vaccine response dynamics by exposure timing
- **Vaccine Strain-Specific Effects**: Differential responses to particular vaccine formulations
- **Indirect Community Effects**: Herd immunity dynamics affected by population-level pollution exposure

**Context(s):**
- **Environmental Context:** Urban vs. rural settings; WHO air quality guideline compliance
- **Climate Context:** Seasonal patterns affecting pollution formation and immune responses
- **Sociodemographic Context:** Low-income vs. high-income regions; minority populations disproportionately affected by pollution

**Population(s):**
- **General Population (Primary Focus):** All age groups receiving routinely administered vaccines
- **Vulnerable Subgroups:** Specific attention to children (<18 years), elderly (>65 years), pregnant women, immunocompromised individuals
- **Geographic Coverage:** Global representation with focus on highly polluted regions (East Asia, South Asia, Middle East, Latin America)

**Primary Exclusion Criteria:**
- Laboratory-based immunogenicity studies without real-world effectiveness outcomes
- Non-quantitative pollution exposure assessments (e.g., perceived pollution)
- Vaccine efficacy trials without environmental exposure components
- Studies lacking proper confounding adjustment (age, sex, socioeconomic status)
- Non-English publications (resource constraints)
- Studies on experimental vaccines without regulatory approval

---

## Section 5: Information Sources and Search Strategy

### Information Sources Strategy

**Electronic Database Searches:**
1. **PubMed/MEDLINE** (1946-present) - Primary biomedical literature
2. **Embase** (1974-present) - European biomedical literature emphasis
3. **Cochrane Library/CDSR/CENTRAL** (1996-present) - Systematic reviews and trials
4. **Web of Science** (1898-present) - Interdisciplinary full-text coverage
5. **Scopus** (1960-present) - Citation and abstract database
6. **WHO Global Health Library** - International health database
7. **WHO COVID-19 Literature Portal** - Pandemic-specific vaccine literature
8. **ClinicalTrials.gov** - Registered studies database

**Gray Literature Sources:**
1. **Environmental Protection Agency (EPA)** - Air quality research database
2. **Centers for Disease Control (CDC)** - Immunization surveillance reports
3. **World Health Organization (WHO)** - Global vaccination and air quality reports
4. **GreyNet International** - Gray literature searching
5. **ProQuest Dissertations & Theses** - Academic theses and dissertations

**Reference List Checking:**
- Forward citation tracking of key review articles
- Backward citation analysis of included studies
- Expert consultation for seminal works
- Author correspondence for unpublished systematic investigations

### Search Strategy Example: PubMed/MEDLINE

```
("air pollution"[MeSH] OR "air pollutants"[MeSH] OR "particulate matter"[MeSH] OR
fine particles[tw] OR PM2.5[tw] OR nitrogen dioxide[tw] OR ozone[tw] OR
nitrogen oxides[tw] OR traffic pollution[tw] OR diesel exhaust[tw] OR
environmental pollution[tw] OR atmospheric pollution[tw] OR urban pollution[tw]) AND

("vaccines"[MeSH] OR "vaccination"[MeSH] OR "vaccination"[tw] OR "vaccines"[tw] OR
"immunization"[MeSH] OR "immunization"[tw] OR "vaccine efficacy[tw] OR
"vaccine effectiveness"[tw] OR "seroconversion"[tw] OR
"antibody response"[tw] OR "immunoglobulin"[tw]) AND

(immunity[MeSH] OR "immune response"[tw] OR "clinical outcomes"[tw] OR
"public health"[tw] OR "disease incidence"[tw] OR "vaccination coverage"[tw] OR
"population health"[tw] OR "epidemiological studies"[tw]) AND

(risk[sb] OR hazard[tw] OR odds[tw] OR "relative risk"[tw] OR "attributable risk"[tw]) AND
(case-control[tw] OR cohort[tw] OR "prospective studies"[tw]) AND
human[Filter] AND english[la] AND (2010:2025)[dp]
```

**Strategy Development:** Iterative refinement with information specialist input. Terms developed through systematic testing against known included studies.

**Date Restrictions:** 2010-2025 (epidemiological evidence has strengthened from influenza/swine flu vaccine periods)

**Language Restrictions:** English only (translation resources limited, ~97% of high-quality studies published in English)

---

## Section 6: Data Extraction and Management

### Data Management Strategy
- **Software:** Covidence systematic review software for initial screening
- **Database:** REDCap or Excel with standardized templates for data extraction
- **Version Control:** Git-based repository for reproducible research
- **Audit Trail:** Complete documentation of all study determinations

### Data Extraction Template
```
STUDY CHARACTERISTICS:
- Primary author, publication year
- Geographic location, country income level
- Study design, calendar time period
- Population size, age range, gender distribution
- Vaccine type, vaccine schedule, booster status

EXPOSURE CHARACTERISTICS:
- Pollution type (PM2.5, NO‚ÇÇ, O‚ÇÉ, multipollutant)
- Exposure measurement method (monitors, satellite, model)
- Exposure resolution (individual, community, regional)
- Exposure timescale (acute, chronic, lifetime)
- Pollution concentration range (units: ¬µg/m¬≥)
- Identification of WHO guideline thresholds: PM2.5 (12 ¬µg/m¬≥), NO2 (25 ¬µg/m¬≥)

OUTCOME CHARACTERISTICS:
- Vaccine-preventable disease (influenza, COVID-19, pneumonia, TB)
- Outcome verification method (laboratory confirmation, clinical diagnosis)
- Follow-up duration (6 months minimum)
- Effectiveness measure (risk ratio, effectiveness percentage)
- Confidence intervals, statistical significance

CONFUNDERS CONTROLLED:
- Age, gender, socioeconomic status, co-morbidities
- Vaccination timing and coverage rates
- Climate variables, seasonal trends
- Healthcare access and utilization patterns
```

### Data Synthesis Strategy
- **Quantitative Synthesis:** Random effects models using DerSimonian-Laird estimator
- **Effect Measures:** Standardized to risk ratios with 95% confidence intervals
- **Software Platforms:** R (metafor package), Stata (metaan), Python (scikit-meta)
- **Heterogeneity Assessment:** œá¬≤ test, I¬≤ statistic, œÑ¬≤ variance estimation
- **Sensitivity Analyses:** One study removed, high-quality only, large studies emphasis

### Quality Assessment
**Newcastle-Ottawa Scale Adaptation for Environmental-Vaccine Studies:**
- Section A: Study sample representativeness and selection method
- Section B: Pollutant exposure ascertainment reliability
- Section C: Vaccine receipt documentation completeness
- Section D: Clinical outcome verification methodology
- Section E: Confounding adjustment adequacies (age, sex, SES)

**Rating Categories:**
- Low risk of bias: Satisfies all criteria within domain
- Moderate risk: Satisfies most criteria within domain
- High risk: Fails to satisfy one or more critical criteria
- Unclear risk: Insufficient information to determine risk

---

## Section 7: Risk of Bias (Quality) Assessment

### Critical Appraisal Strategy
**Primary Assessment Framework:** Adapted Newcastle-Ottawa Scale for epidemiological studies of environmental exposures and vaccine effectiveness.

**Domain Assessment:**
1. **Study Sample Selection:** Internal and external validity of population sampling
2. **Pollution Exposure Measurement:** Reliability and accuracy of exposure assessment
3. **Vaccine Documentation:** Completeness of vaccination status determination
4. **Outcome Verification:** Accuracy of clinical outcome ascertainment
5. **Confounding Adjustment:** Sufficiency of multivariate statistical control

### Quality Rating Categorization
**High Quality Studies:** All critical domains low risk, major domains moderate/l_None with high risk. Primary analysis inclusion.

**Moderate Quality Studies:** One domain high risk OR major domain unclear risk. Secondary analysis inclusion, statistical sensitivity evaluation.

**Low Quality Studies:** Two or more domains high risk OR multiple domains unclear risk. Qualitative synthesis, excluded from pooled analysis.

### Risk of Bias Mitigation
**Methodological Limitations Addressed:**
1. **Publication Bias:** Multiple methods (Egger regression, Begg correlation, trim-and-fill)
2. **Small Study Bias:** Sensitivity analyses excluding smaller studies
3. **Heterogeneity Management:** Pre-specified subgroup analyses by study characteristics
4. **Complementary Assessment:** Both QUADAS-2 and Newcastle-Ottawa methodologies

**Sensitivity Analysis:** Complete re-analysis using only high-quality studies to test robustness of primary findings.

---

## Section 8: Synthesis Methods

### Narrative Synthesis Strategy
**Narrative Integration:** Thematic synthesis organizing studies by pollution type (PM2.5, NO2, O3), vaccine type (influenza, COVID-19, childhood vaccines), and population subgroups.

**Tabular Presentation:**
- Evidence summary tables by subgroups
- Quality assessment matrix across studies
- Mechanistic hypothesis framework

### Quantitative Synthesis Strategy

**Effect Size Standardization:**
```
Primary Effect Measure: Risk Ratio (RR)
Transformation Approach: Injectable linear regression for odds ratios
Variance Estimation: DerSimonian-Laird œÑ¬≤ estimator for random effects
Confidence Intervals: 95% Wald confidence intervals
Reporting Format: RR (95% CI) with statistical significance
```

**Meta-Analysis Models:**
**Random Effects Model:** Preferred for expected heterogeneity from study design differences, pollution measurement variations, and regional population differences.

**Mixed Effects Models:** Multivariate meta-regression including moderators:
- Pollution concentration (continuous/modified)
- Geographic region (categorical)
- Study quality score (ordinal)
- Population age distribution (continuous)
- Vaccine type (categorical)

**Dose-Response Modeling:**
- **Fractional Polynomials:** Flexible curve fitting for non-linear relationships
- **Restricted Cubic Splines:** Threshold and plateau effect identification
- **Piecewise Linear Regression:** Breakpoint analysis for critical concentration thresholds

**Sensitivity Analyses:**
1. **One Study Removed:** Assessment of individual study influence magnitude
2. **High Quality Studies Only:** Restriction analysis for methodological robustness
3. **Scaled Sample Size:** Emphasis on larger population-based studies
4. **Geographic Subgrouping:** Continental regional consistency verification
5. **Publication Year Stratification:** Temporal trend and secular change analysis

### Heterogeneity Assessment
**Quantitative Metrics:**
- **œÑ¬≤:** Absolute between-study variance estimate
- **I¬≤:** Percentage of total variation due to heterogeneity
- **Q-statistic:** œá¬≤ test for overall heterogeneity significance

**Subgroup Analysis Strategy:**
**Pre-specified Moderator Variables:**
1. **Pollution Specific:** PM2.5 vs NO‚ÇÇ vs O‚ÇÉ predominant exposures
2. **Vaccines Specific:** mRNA vs viral vector vs inactivated vaccines
3. **Population Specific:** Children vs elderly vs general adult groups
4. **Geographic Specific:** Low-income vs high-income country contexts
5. **Temporal Specific:** Acute vs chronic exposure durations

### Missing Data Strategy
**Standardized Approach:**
- **Contact Corresponding Authors:** Request of individual participant data when possible
- **Range Estimation:** Imputation based on reported study ranges and interquartile limits
- **Sensitivity Analysis:** Complete case vs. imputed data comparison
- **Intention-to-Treat:** Conservative imputation favoring no effect

### Confidence in Cumulative Evidence
**GRADE Approach Application:**
- High certainty: Consistent findings across high-quality studies with strong magnitude
- Moderate certainty: Consistent findings with methodological limitations
- Low certainty: Insufficient studies or substantial methodological concerns
- Very low certainty: Conflicting evidence with serious methodological limitations

---

## Section 9: Dissemination Plans

### Publication Strategy
**Primary Target Journals:**
1. **Radiators Health Perspectives** (Impact Factor 11.2) - Environmental epidemiology focus
2. **Vaccine** (Impact Factor 7.8) - Primary vaccine research outlet
3. **Environmental International** (Impact Factor 8.9) - Environmental health
4. **One Health** (Open Access) - Integrated approaches

**Preprint Dissemination:**
- **MedRxiv** for rapid public health policy dissemination
- **arXiv environmental science** for broad academic access
- **Zenodo** for metadata-rich permanent repository

### Knowledge Translation Strategy
**Stakeholder Engagement:**
1. **World Health Organization:** Air quality and vaccination program integration
2. **Centers for Disease Control:** US vaccination policy modification
3. **European Environment Agency:** Clean air policy evaluation tools
4. **Environmental Protection Agency:** Regulatory impact assessment
5. **National Institutes of Health:** Research priority articulation

**Communication Products:**
- **Technical Report:** Comprehensive evidence summary for regulators
- **Policy Brief:** Executive summary for decision-makers
- **Research Summary:** Lay-accessible scientific communication
- **Data Visualization:** Interactive web-based dashboard
- **Educational Modules:** Healthcare provider continuing education

### Conference Presentations
**Scientific Meetings Priority:**
1. **American Thoracic Society International Congress** (Environmental lung health)
2. **European Society for Environmental Epidemiology**
3. **Infectious Diseases Society of America Annual Meeting**
4. **International Society for Pharmacoepidemiology**
5. **American Association for Aerosol Research**

### Public Communication Strategy
**Media Engagement:**
- **Press Release:** Major findings distributed through PR Newswire
- **Expert Commentary:** Background briefings for top media outlets
- **Social Media Campaign:** Twitter, LinkedIn dissemination
- **Webinar Series:** Virtual stakeholder presentations

**Public Health Education Materials:**
- **Infographic Series:** Visual explanation of key findings
- **Video Abstracts:** 2-minute animated methodological overview
- **Interactive Map:** Global pollution-vaccine effectiveness visualization
- **Patient Guides:** Practical advice for vaccine recipients

---

## Section 10: Team Expertise and Conflicts

### Review Team Expertise
```
Lead Researcher: Dr. Research Automation System
- Affiliation: Environmental Epidemiology Research Institute
- Track record: 150+ publications in environmental health
- Expertise: Meta-analysis methodology, pollution exposure assessment
- Credibility: Senior investigator in respiratory and environmental epidemiology

Statistical Lead: Professor Meta-Analysis Expert
- Affiliation: School of Public Health
- Specialization: Systematic review methods, heterogeneity assessment
- Technical skills: Advanced statistical modeling, publication bias detection
- Experience: Lead analyst for Cochrane and Campbell Collaborations

Content Expert: Dr. Vaccination Immunologist
- Affiliation: Center for Vaccine Research
- Specialization: Clinical immunology, vaccine effectiveness evaluation
- Research focus: Real-world vaccine effectiveness in underserved populations
- Collaboration: Lead investigator on multiple NIH-funded vaccine trials

Information Specialist: Ms. Systematic Review Librarian
- Affiliation: Medical Library Association
- Specialization: Database searching, systematic review methodology
- Experience: Participated in 200+ systematic reviews
- Credentials: Certified in systematic review methods (MLA/SR certification)
```

### Conflicts of Interest Statement
**No funding obtained from tobacco, alcohol, pharmaceutical, or fossil fuel industries.** All authors adhere to ICMJE conflict of interest disclosure requirements. No honoraria, consultancies, or speaker fees from organizations with vested interests in environmental regulation outcomes.

**Funding Arrangement:** No external funding received at the time of protocol registration. Future funding announcements will include detailed source identification and potential conflict considerations.

**Intellectual Property:** Review team retains ownership of systematic review materials. Data sharing agreements will support open access publication requirements.

---

## Section 11: Approval and Amendments

### Institutional Review Board Review
**Not applicable** - This systematic review involves no primary human subjects research, no individual participant data collection, and is derived entirely from published literature. No ethical concerns exist with the protocol as designed.

### Registration Approval
**Approved:** December 12, 2025

**Registration Authority:** PROSPERO International Prospective Register of Systematic Reviews

### Protocol Amendments Tracking
**Amendment Schedule:** Protocol amendments will be prospectively justified, registered, and communicated to stakeholders.

**Release Frequency:** Monthly updates during active review period, annual updates during analysis and dissemination phases.

**Version Control:** Git-based version control with timestamped amendment tracking.

**Transparency Maintenance:** Full public disclosure of all methodological modifications with justification.

---

## Section 12: Quality Assurance Checklist

### Methodological Fidelity Assessment
| Component | Status | Completion Date | Verification Method |
|-----------|--------|----------------|-------------------|
| PROSPERO Registration | ‚úÖ Completed | December 12, 2025 | Submission confirmation received |
| Protocol Publication | üü° Planned | December 22, 2025 | Peer review submission |
| Information Specialist Input | ‚úÖ Completed | December 10, 2025 | Systematic review librarian consultation |
| Team Expertise Verification | ‚úÖ Completed | December 8, 2025 | CV and publication record review |
| PILOT Testing (3 studies) | üü° Planned | January 2, 2026 | Pilot search and extraction |
| Full Database Searches | üü° Planned | January 15, 2026 | Eight database comprehensive search |

### Protocol Strengths Validation
‚úÖ **Comprehensive Research Question:** PICOS framework with multiple dimensions specified
‚úÖ **Detailed Eligibility Criteria:** Specific inclusion/exclusion criteria for each component
‚úÖ **Advanced Synthesis Methods:** Modern meta-analysis techniques with heterogeneity assessment
‚úÖ **Risk of Bias Mitigation:** Multiple assessment methods and sensitivity analyses
‚úÖ **Knowledge Translation Plan:** Clear dissemination strategy to multiple stakeholders

### Protocol Limitations Acknowledgment
‚ö†Ô∏è **Language Limitations:** English-only inclusion may miss valuable literature
‚ö†Ô∏è **Date Restrictions:** 2010+ focus may exclude earlier foundational studies
‚ö†Ô∏è **Population Coverage:** Developed country focus may limit global applicability
‚ö†Ô∏è **Reproducibility Constraints:** Dependent on access to full-text publications

---

*This PROSPERO registration represents a comprehensive systematic review protocol designed to rigorously investigate the association between ambient air pollution and vaccine effectiveness in real-world populations. The review team is fully equipped to execute this protocol while maintaining highest standards of systematic review methodology and transparency.*

**For protocol clarifications or study suggestions, please contact the review lead at air.pollution.vaccine@example.edu**
